Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466791 · ClinicalTrials.gov registry record · Phase 2
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
A Phase 2 study of Attention Deficit Disorder With Hyperactivity, sponsored by Noven Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT00466791: Completed Phase 2 study of Attention Deficit Disorder With Hyperactivity, sponsored by Noven Therapeutics.
NCT00466791 is a Phase 2 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Noven Therapeutics. The registered enrollment target is 93 participants, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00466791, a Phase 2 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Noven Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
Conditions Studied
Interventions
- DRUG Methylphenidate Transdermal System
Study Locations (1)
California
- UCI Child Development Center - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00466791 record still lists
NCT00466791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate Transdermal System is the first listed.
NCT00466791 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00466791 about?
NCT00466791 is a clinical study titled "Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD". Evaluate the behavioral effects of MTS in children aged 6-12 with ADHD
What is the current status of trial NCT00466791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2004-08. Estimated completion is 2005-05.
What conditions does trial NCT00466791 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT00466791?
The interventions under investigation include: Methylphenidate Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00466791?
This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00466791 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00466791's enrollment target sits among peer trials
93 12th of 20 higher than 8 of 20 other Attention Deficit Disorder With Hyperactivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
COMPLETED · Phase 2
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia